To the full analysis
Buyback calculator for TG Therapeutics
TG Therapeutics stock: key metrics
TGTXTG Therapeutics had an operating margin of 20% and a return on invested capital (ROIC) of 26.5% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | no data | no data | no data |
| 2007 | no data | no data | no data |
| 2008 | no data | no data | no data |
| 2009 | no data | no data | no data |
| 2010 | no data | no data | no data |
| 2011 | no data | no data | no data |
| 2012 | 100.0% | −141,196.4% | −94,879.9% |
| 2013 | 100.0% | −15,071.4% | −13,438.8% |
| 2014 | 100.0% | −36,567.0% | −36,606.5% |
| 2015 | 100.0% | −41,461.9% | −41,310.0% |
| 2016 | 58.7% | −51,823.5% | −51,353.4% |
| 2017 | 46.0% | −77,904.6% | −77,749.9% |
| 2018 | 42.1% | −114,736.8% | −114,132.9% |
| 2019 | 100.0% | −111,220.4% | −113,730.9% |
| 2020 | 100.0% | −179,996.1% | −183,803.3% |
| 2021 | 88.2% | −5,154.3% | −5,204.1% |
| 2022 | 90.5% | −7,839.0% | −8,036.3% |
| 2023 | 94.0% | 8.8% | 5.4% |
| 2024 | 88.3% | 12.7% | 7.1% |
| 2025 | 83.7% | 20.0% | 72.6% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | no data | −100.0% |
| 2007 | 200.0% | no data | −100.0% |
| 2008 | 97.6% | no data | −100.0% |
| 2009 | 41.2% | no data | −100.0% |
| 2010 | −11.6% | −49.7% | 3.3% |
| 2011 | −8.9% | −7.9% | −5.4% |
| 2012 | −100.0% | no data | −81.9% |
| 2013 | −51.1% | −57.6% | −42.6% |
| 2014 | −69.6% | −70.8% | −64.3% |
| 2015 | −62.0% | −53.9% | −55.5% |
| 2016 | −100.0% | −88.4% | −100.0% |
| 2017 | −100.0% | no data | −100.0% |
| 2018 | −100.0% | no data | −100.0% |
| 2019 | −100.0% | no data | −100.0% |
| 2020 | −53.8% | −67.7% | −44.7% |
| 2021 | −100.0% | −62.2% | −91.7% |
| 2022 | −100.0% | −75.7% | −100.0% |
| 2023 | 7.9% | 9.6% | 3.8% |
| 2024 | 10.5% | 35.0% | 4.0% |
| 2025 | 69.0% | 26.5% | 42.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.